Arginine-Vasopressin Dynamics in Relation to Food Intake and 8-Week Intranasal Oxytocin Treatment in Adults With Obesity
Authors' conclusion
AVP levels decreased after food intake in adults with obesity, indicating a potential disruption in AVP signaling and possibly underlying obesity pathophysiology. Chronic IN OXT administration did not alter AVP levels, supporting safety of OXT-based therapeutics.
Study context
- Population
- Adults with obesity (56% women, age 33.7 ± 6.3 years), tertiary academic center61 randomized
- Participants
- 63 adults
- Comparison
- 8-W intranasal oxytocin (OXT) vs placebo; Arginine-vasopressin (AVP) around a standardized meal
- Primary endpoint
- AVP levels before and 30, 60 and 120 minutes after a standardized meal at baseline, and W4, 6 and 8 after starting OXT or placebo
Methodological detailscross-sectional and longitudinal data, randomized 1:1, placebo-controlled, 8-week, tertiary academic center
- Cross-sectional and longitudinal data
- Randomized 1:1
- Placebo-controlled
- 8-week
- Tertiary academic center
Primary result
As reported in the abstract
AVP levels after standardized meal vs fasting · 60 minutes after meal
- AVP at 60 minutes, adjusted mean ± SE
- 68.55 ± 9.64 pg/mL
- AVP fasting, adjusted mean ± SE
- 80.99 ± 11.22 pg/mL
- AVP levels did not significantly change over 8-W intranasal (IN) OXT vs placebo
- P ≥ .544
Further findings
- No effect of BMI on AVP levels
- P ≥ 0.615
- No effect of sex on AVP levels
- P ≥ 0.498
Original publication
Arginine-Vasopressin Dynamics in Relation to Food Intake and 8-Week Intranasal Oxytocin Treatment in Adults With Obesity. J Clin Endocrinol Metab. Published 2 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →